{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:20:45Z","timestamp":1793496045273,"version":"4.5.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.parkreldis.2009.05.006","type":"journal-article","created":{"date-parts":[[2009,6,13]],"date-time":"2009-06-13T09:04:59Z","timestamp":1244883899000},"page":"71-72","source":"Crossref","is-referenced-by-count":51,"title":["Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations"],"prefix":"10.1016","volume":"16","author":[{"given":"Teus","family":"van Laar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martje","family":"Drent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2009.05.006_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","article-title":"Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease","volume":"21","author":"Deleu","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.parkreldis.2009.05.006_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.20308","article-title":"Repeated visual hallucinations in Parkinson's disease as disturbed external\/internal perceptions: focused review and a new integrative model","volume":"20","author":"Diederich","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2009.05.006_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","article-title":"Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment","volume":"3","author":"Ellis","year":"1997","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2009.05.006_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.54.4.372","article-title":"Subcutaneous apomorphine for Parkinsonian patients with psychiatric side effects on oral treatment","volume":"54","author":"Ray-Chaudhuri","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802009001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802009001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T01:28:28Z","timestamp":1545182908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802009001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1353802009001333"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2009.05.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}